Trial Search Results

P1/2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform

The purpose of this study is to investigate the safety and effectiveness of a combination treatment for glioblastoma multiforme utilizing radiotherapy with the FDA approved chemotherapy drug temozolomide

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University


  • Drug: Temozolomide
  • Procedure: Stereotactic Radiosurgery


Phase 1/Phase 2


Inclusion Criteria:

   - Histopathologically confirmed newly diagnosed glioblastoma multiforme. Diagnosis must
   be made by surgical biopsy or excision

   - The tumor must be supratentorial in location

   - The planning target volume (tumor plus margin) must measure ≤ 150 cm^3 in volume

   - Age ≥ 18 years

   - Life expectancy of at least 12 weeks

   - Patient must have adequate organ function to tolerate temozolomide (details in the

Exclusion Criteria:

   - Patients who have previously been treated with brain irradiation to the region that
   would result in overlap of the radiation fields

   - Tumor foci detected below the tentorium

   - Multifocal disease or leptomeningeal spread

   - Prior allergic reaction to the study drugs involved in this protocol

   - Patients with pacemaker will be allowed to undergo CT instead of MRI

   - Pediatric patients (age < 18), pregnant women, and nursing patients will be excluded

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting